LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...
News
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer’s Disease
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company...
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio...
BrightSpring Health Services, Inc. Welcomes Dr. Steve Miller to Board of Directors
LOUISVILLE, Ky., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider...
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage...
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
Clinical data demonstrated treatment with AGA2118 resulted in dose-dependent increases in bone mineral densityWOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for...
BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding...
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and...
Novellia and University of Alabama at Birmingham Study Examines Biomarker Testing Practices for Non-Small Cell Lung Cancer
- Research study presented at the 2024 ASCO Quality Care Symposium uses Novellia's AI-enabled technology and personal health record platform to...
Tinley’s Launches Hemp Delta 9 THC-Infused Beckett’s Tonics At Total Wine & More
Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - September 30, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:...
Digital & Intelligent Pathway: Xiaohongshu and VOGUE Business Unveil Groundbreaking Lifestyle Marketing Insights at Milan Summit
MILAN, Sept. 30, 2024 /PRNewswire/ -- As the exclusive strategic partner, Xiaohongshu teamed up with VOGUE Business to host the...
Xiaohongshu x VOGUE Business Unveils New Horizons in Healthcare and Wellness at Milan Summit
MILAN, Sept. 30, 2024 /PRNewswire/ -- From September 26 to 27, Xiaohongshu partnered with VOGUE Business to host the Digital Silk...
NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics
Scalable and adaptable, TETRIS captures the diversity of protein interactions on site to inform accurate cancer diagnoses, enabling the personalisation...
T2D.com Announces That Former NFL Linebacker Alec Ogletree Has Joined the Company as a Co-Founder
Alec Ogletree, former NFL linebacker that in retirement has been investing in and helping build consumer centric companies serving people...
Digicann Ventures Signs Definitive Agreement for Proposed RTO Transaction with 3Win Corp.
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia,...
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by...
GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary...